Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: Part 3 of the open-label, multicenter, phase 1b PAVO study Research Letter

  

Authors:	Nahi, H.; Usmani, S. Z.; Mateos, M. V.; van de Donk, N. W. C. J.; Oriol, A.; Plesner, T.; Bandyopadhyay, N.; Hellemans, P.; Tromp, B.; Nnane, I.; Zemlickis, D.; Chari, A.; Moreau, P.
Title:	Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: Part 3 of the open-label, multicenter, phase 1b PAVO study
Keywords:	clinical trial; antineoplastic agent; multiple myeloma; antineoplastic combined chemotherapy protocols; dexamethasone; plasmacytoma; monoclonal antibody; antibodies, monoclonal; multicenter study; phase 1 clinical trial; corticosteroid; neoplasms, plasma cell; adrenal cortex hormones; humans; human; daratumumab
Journal Title:	Leukemia and Lymphoma
Volume:	64
Issue:	2
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2023-01-01
Start Page:	468
End Page:	472
Language:	English
DOI:	10.1080/10428194.2022.2148221
PUBMED:	36593729
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145504293&doi=10.1080%2f10428194.2022.2148221&partnerID=40&md5=115340bfc5ac336770a72822ce78083c
Notes:	Letter -- Export Date: 1 March 2023 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/203457